Free tool
FAERS Monitor: Avagard
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021074 or its brand name (Avagard, Alcohol, Chlorhexidine Gluconate). Reports on generic versions are filed under their own applications.
Reports
5
Serious
4
80% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash2
- rash pruritic2
- burns second degree1
- burns third degree1
- eye irritation1
- urticaria1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2020 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,154 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| burns third degree | 1 | 3991.3 | 690.7 | 996 |
| burns second degree | 1 | 2399.3 | 415.4 | 599 |
| rash pruritic | 2 | 155.2 | 53.1 | 172 |
| eye irritation | 1 | 73.1 | 12.7 | 17 |
| urticaria | 1 | 25.1 | 4.4 | 5 |
| rash | 2 | 19.3 | 6.6 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.